戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (right1)

通し番号をクリックするとPubMedの該当ページを表示します
1 ing platform, only 15% of these trials and 29% of phase 3/4 trials have been accessed by investigators thus far, and a ne
2                                         Traditionally, such trials have been based on classical statistics.
3                                 To date, precision oncology trials have been based on molecular matching with predetermin
4 ential as genotypes in this region (where very few clinical trials have been carried out) are distinct from those found i
5                 Recently, a number of randomized controlled trials have been completed and the first drugs, all therapeut
6                                   Similarly, fewer clinical trials have been completed in PDAC (n = 608) compared with br
7                                 Few cardiovascular outcomes trials have been conducted for obesity treatments.
8 lt patients with idiopathic pulmonary fibrosis, no clinical trials have been conducted in a pediatric population using ag
9              Accordingly, Dex-based phase I and II clinical trials have been conducted in advanced malignancies, showing
10                                 As of now, several clinical trials have been conducted to assess the benefits of TRT-base
11 type 2 diabetes mellitus, many large randomized, controlled trials have been conducted with the primary goal of assessing
12            To address this, several treatment de-escalation trials have been conducted, but only a few of these have prov
13 yond the narrow range of settings and populations for which trials have been conducted.
14             For two stimulation targets, pivotal randomized trials have been conducted; both failed a futility analysis.
15                                        Unfortunately, these trials have been designed without a strong foundational knowl
16                                           However, clinical trials have been disappointing in part to dose-limiting hyper
17 atment of children in high-income countries, no substantive trials have been done of the interventions adapted for use in
18                                  Few high quality treatment trials have been done on psychiatric disorders in prisoners.
19                 However, physicians rarely intervene and no trials have been done on the subject.
20 dical need via improved glycaemic control, several clinical trials have been done to assess the efficacy and safety of SG
21                                    No randomised controlled trials have been done to identify the optimum treatment for t
22                                                    No large trials have been done to investigate the efficacy of an inter
23                                  An unprecedented number of trials have been done, initiated, or are planned to test new
24  trials and case reports, but several randomised controlled trials have been done, particularly focused on the effects of
25  cirrhosis, but no adequately powered randomised controlled trials have been done.
26 n resistance (IR); however, results from human intervention trials have been equivocal.
27 adverse events reported less frequently in earlier clinical trials have been experienced more frequently in real-world pr
28 ocardial injury; however, the benefits observed in clinical trials have been generally less consistent.
29                                            Several of these trials have been hindered by very low matching rates, often i
30 ht how the dialogue has changed and how successful clinical trials have been implemented.
31 ic regulation therapy for HFrEF, results of larger clinical trials have been inconsistent.
32 es have shown that placebo response rates in antidepressant trials have been increasing since the 1970s.
33                 Causes of placebo effects in antidepressant trials have been inferred from observational studies and meta
34 ive in specific Ph-like ALL subsets, and precision medicine trials have been initiated for this high-risk ALL subset.
35                                           Numerous clinical trials have been launched to identify effective treatments fo
36  a patient who had been receiving ICI, hundreds of clinical trials have been launched with the aim of testing the safety
37                                           Existing clinical trials have been limited by short duration, low doses of vita
38                                      Although some clinical trials have been performed using MIRET, it is hoped that such
39                                       Several breast cancer trials have been performed with the PET tracers (18)F-FDG, 3'
40  the spectrum of HF, preliminary results from many phase II trials have been promising but are frequently followed by uns
41              Although results of intravenous iron repletion trials have been promising, regularly treating patients with
42 dvances have been made and, recently, randomized controlled trials have been published helping clinicians' management of
43  yet been conclusively determined as no randomized clinical trials have been published on this issue, and their effective
44  prevention of SSI is based on low-level evidence, and many trials have been published since.
45                           Two blinded randomized controlled trials have been published, one with level I evidence (Yale-B
46 e was provided, the results of early phase 1 and 2 clinical trials have been quite disappointing to date, and toxicities
47                            For many years, oncology phase I trials have been referred to as 'toxicity trials' and have be
48             Although risk reductions observed in randomized trials have been relatively consistent across series, the abs
49                                                    However, trials have been relatively scarce and limited in sample size
50                             Recently, gene therapy clinical trials have been successfully applied to hemoglobinopathies,